CN1379109A - Adenovirus carrier for specifically killing primary liver cancer cells and its application - Google Patents
Adenovirus carrier for specifically killing primary liver cancer cells and its application Download PDFInfo
- Publication number
- CN1379109A CN1379109A CN 01134314 CN01134314A CN1379109A CN 1379109 A CN1379109 A CN 1379109A CN 01134314 CN01134314 CN 01134314 CN 01134314 A CN01134314 A CN 01134314A CN 1379109 A CN1379109 A CN 1379109A
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- gene
- sequence
- cell
- adenovirus carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method and its composition, based on viro therapy, for treating primary liver cancer expressing alpha-fetoprotein are disclosed. Two genetically engineered recombinant adenoviruses containing alpha-fetoprotein promoter and isolator genes are configured. The adenovirus containing alpha-fetoprotien can specifically copied in tumor cell and the said isolator can improve the specificity of copying the recombinant adenovirus in the said liver cancer cell. Test results show that these two adenoviruses can be used for viro therapy and gene therapy of primary liver cancer.
Description
Invention field:
The present invention relates to gene therapy and viral therapy field, be specifically related to utilize that tumor-specific promoters control virus vector is specific specially in the liver cancer cell of expressing alpha-fetoprotein duplicates and express, thereby kill the technology of liver cancer cell.Background of invention:
The gene therapy of malignant tumour requires virus vector specificly efficiently to enter tumour cell, the express therapeutic gene, or specificly in tumour cell, duplicate, and then the kill tumor cell.
At present the common vector as gene therapy has retroviral vector, adenovirus carrier and gland relevant viral vector, wherein as therapy of tumor comparatively commonly used be adenovirus carrier.
Adenovirus is a kind of double-stranded DNA virus, and its genome length is about 36kb, is divided into early transcription district and late transcription district.Find that at present adenovirus hominis has 47 serotypes, adheres to A-F6 subgenus separately, wherein to be that present people study the most detailed a kind of for 5 type adenovirus of C subgenus.
Adenovirus is deleted the resulting adenovirus carrier in E1 district and E3 district often be called as first-generation adenovirus carrier, it is that 8kb is with interior foreign gene that this carrier can insert and express length, this adenovirus carrier not reproducible itself produces progeny virus, and adenovirus carrier DNA also unconformability goes in the genome of host cell.
Adenovirus carrier can infect the broad variety cell, comprises cell stationary phase.Adenovirus carrier is large scale culturing and obtain the viral pure product of high titre easier.These characteristics make adenovirus as therapy of tumor carrier commonly used.
Adenovirus is as the carrier of therapy of tumor, and it is crucial improving its specificity to tumour cell.
In recent years, the development of genetic treatment of tumor theory and practice is very fast, in the various schemes that adopt gene therapy means treatment tumour, allow recombinant virus is specific to be duplicated and express in tumour cell, thereby the so-called oncolytic virus of kill tumor cell (Oncolytic Virus) scheme, progress is the fastest at present, and representative wherein is the recombinant adenovirus Onyx-15 of U.S. Onyx company exploitation, is carrying out the III clinical trial phase at present.
In order to improve the specificity of virus vector killing tumor cell, it is very important to seek tumour cell and Normocellular difference.
Many at home and abroad investigators all make great efforts to develop and can specificity duplicate the virus vector of expression in liver cancer cell, someone attempts to reach this purpose (Lieber by transforming adenoviral gene group itself, A.et.al.), someone attempts to reach this purpose (Curiel by the ciliary structures of modifying adenovirus, D.at.al.), wherein, duplicating with the tumor-specific promoters control recombinant virus specificity of external source, is a kind of important techniques means.(Yu，D.C.et.al.)
An important difference of primary hepatic carcinoma cell and normal liver cell is surpass 70% primary hepatic carcinoma cell expressing alpha-fetoprotein, and normal liver cell not to be expressed, has only fetal liver cell just to express this albumen.This is a kind of embodiment of cancer cells primitivization, and in clinical diagnosis, it is the important census method of primary hepatic carcinoma that alpha-fetoprotein detects.Therefore, whether express the vital signs that alpha-fetoprotein is difference normal liver cell and liver cancer cell.If with himself promotor deletion in the adenovirus, be replaced as the promotor of alpha-fetoprotein, like this, this recombinant adenovirus will place under the afp promoter control, only in the cellular environment of expressing alpha-fetoprotein, because have the incitant of this promotor, so promotor is activated, viral genome begins to duplicate and express.And in normal liver cell, not having such incitant, viral genome can not be duplicated expression.So just caused selective killing to liver cancer cell.
At present, existing several study group adopt afp promoter control adenovirus, in the hope of reaching the effect of special anti-liver cancer.Because the structure of afp promoter is very complicated, use distinct portions, different structures can draw different structures, and Here it is be that assorted petty a lot of study group specificity of reporting afp promoter is undesirable.
We have carried out a large amount of research in this respect, have used a kind of afp promoter of special construction, contain enhanser (Enhancer), the son of mourning in silence (Silencer) and promotor core area repertoire parts such as (core promoter).
The problem that the external source tumor-specific promoters may run into is the fidelity degree of promotor, promptly whether can keep same specificity in the heterologous gene group.In order to strengthen the specificity of afp promoter, we have inserted specific genes regulation and control assembly-separaant (ioslator) before the afp promoter gene order in the recombinant adenovirus genome, make it reach very high specificity.
For the therapy of tumor carrier, require it to produce specificity on the one hand at tumour cell; On the other hand, wish that also it has Antioncogene, place under the tumor-specific promoters control, specificly in tumour cell, express, improve fragmentation effect tumour cell.Simultaneously, require it in normal cell, not duplicate as far as possible, lower and kill and wound Normocellular.For reaching this two purposes, A5 type adenovirus E 1 a gene is incorporated into produces an ideal results in the viral genome.
5 type adenovirus E 1 a genes are positioned at the viral genome left end, have 84% conservative property is arranged.E1a two the main albumen of encoding, one have 243 amino acid (12S, 243R), one have 289 amino acid (13S, 289R).E1a-12S and E1a-13S albumen impel virus replication by the expression that activates virogene.(Shenk，T。1996。Adenoviridea，P。2111-2148。) E1a-12S and E1a-13S albumen is initial two albumen of expressing of adenovirus, have the function that activates adenovirus other gene, particularly E2 district and E4 district gene, and the function in these two districts is duplicating of relevant adenovirus.
E1a direct activation cytogene, the inducing cell dna replication dna, with cell cycle regulating protein matter pRb, pRb associated protein (P107/P130) or P300 interact.
E1a combines with pRb family protein molecule, discharges the transcription factor of E2F family, causes in the host cell some relative dna synthetic genes by positive regulation, makes the stationary phase cell enter the S phase.These and some other in S phase activated cytokine, produced a suitable viral DNA synthetic environment.In normal cell, E1a inducing cell cycle negative regulation causes the proteic accumulation of P53, stimulates P53 mediation G1 phase cell to stagnate (e1-Deiry, W.S。et。al。，1993。Cell。75：817-25；Xiong，Y。et。al。1993。Nature, 366:701-4) or enter apoptotic pathways.In addition, the E1a inductive is transferred to die and also can be passed through not take place according to the P53 approach.(Teodoro，J。G。et。al。1995。Oncogene。11：467-74)
E1a gene past attempts is considered to an oncogene, can make animal embryo cell generation immortalization, and can interact with the oncogene of other viruses or cell.
In experimentation on animals, E1a can not bring out canceration separately, and needs to concur with other gene such as E1b.5 type adenovirus itself do not have carinogenicity, and other type has the adenovirus of the carinogenicity E1a gene independent with it not have necessary relation.Over past ten years, a lot of experiment confirms, 5 type adenovirus E 1 a genes not only do not have carinogenicity to human body cell, and in fact the effect that suppresses tumor growth can be arranged.The tumor inhibition effect of E1a may be relevant to the regulation and control of several genes with E1a.Mainly show the following aspects: 1. particularly the neck oral squamous cell carcinomas is closely related for overexpression of neu gene and human malignant tumor, and also prognosis and the resistance with tumour is relevant.And evidence show, the E1a gene can specific inhibition neu expression of gene at transcriptional level, can suppress as characteristics relevant such as adhesion, invasion and attack with metastases, the E1a gene also can suppress the canceration characteristic that the oncogene inductive comprises cell polymorphism etc., also can improve susceptibility (Yu DH, the et.al.Molecular basis of oncology.1995:131-162 of the breast cancer cell of high expression level neu gene to chemotherapeutics; Ueno NT, et.al.Proc AACR, 1998,39:360 (Abstract)) 2. E1a produce antitumor action by improving the horizontal cell death inducing of cell P53.3. E1a can improve cell to chemotherapeutic and the apoptotic susceptibility of radiation institute inductive such as 5 FU 5 fluorouracil, cis-platinums.4. E1a can express at host cell surface, and killing and wounding, removing of the cell of raising body pair cell expression E1a gene reaches antitumous effect.
As therapy of tumor, existing issue is to improve its expression in tumour cell specifically, and the recombinant adenoviral vector under the afp promoter control has this feature, and the E1a gene applies in the clinical trial in recent years as Antioncogene.The inventor is through research trial, with the promotor deletion of 5 type adenovirus E 1 districts, replace afp promoter, tumour-specific for research afp promoter and separaant, and at afp promoter gene back connection reporter gene alkaline phosphatase gene, construct a kind of new therapy of tumor adenovirus carrier M001, in M001 recombinant adenovirus virus gene, insert separaant before the afp promoter gene, construct another kind of recombinant virus M002.For carrying out practical application, with the alkaline phosphatase gene place to go in above two recombinant adenoviral vectors, replace adenovirus E 1 a gene, form two tumour-specific virus vector A001 and A002, purpose provides a kind of adenovirus carrier and can specificly duplicate in liver cancer cell, express the E1a gene, thus differential high efficient kill liver cancer cell.
Constructed recombinant virus M002 has delivered Chinese typical culture collection center preservation among the present invention, and the address is Chinese Wuhan, in the Wuhan University.Preservation date is October 28 calendar year 2001, and deposit number is V200114, and the classification name is an adenovirus.
The present invention also provides the pharmaceutical composition that contains this tumour-specific vector virus and pharmaceutically acceptable carrier.
The present invention also provides this tumour-specific carrier to be used for the treatment of purposes in the tumors pharmaceutical combination in preparation.Description of drawings: Fig. 1 .M001 and M002 recombinant adenovirus gene structure, wherein AFP is an afp promoter, and AP is an alkaline phosphatase gene, and pA is the poly adenosine, and HS4 is a separaant.Fig. 2 .A001 and A002 recombinant adenovirus gene structure, wherein AFP is an afp promoter, and AP is an alkaline phosphatase gene, and pA is the poly adenosine, and HS4 is a separaant.Fig. 3 .M001 and the test of M002 recombinant adenovirus cell-specific, wherein M1 is a M001 virus, M2 is a M002 virus, and Hep3B is the Bel7402 for the human hepatoma cell line HepG2, and HuH7 is the Bel7402, BT549 is a MCF-7, Fibroblast is the human fibroblasts, and Humhep is people's hepatic cell line, and MCF-7 is a MCF-7, LS174T is a CCL188, and HeLa is people's cervical cancer tumer line.Detailed Description Of The Invention:
Constructed recombinant adenoviral vector is 5 type adenovirus through transforming among the present invention.The genome of 5 type adenovirus contains 35935 Nucleotide.5 type adenovirus are a kind of virus of studying at present.Mainly cause people's respiratory tract infection on the epidemiology, tangible self-healing property is arranged.Adenovirus is applied to the human body history of existing decades as vaccine, transforms human normal cell line and the generation of carcinogenic phenomenon from finding no.
M001 and the M002 that shows that make among the recombinant adenoviral vector that the present invention is constructed such as Fig. 1.In M001, the promoter region of adenovirus carrier E1a is deleted, adds duplicating of afp promoter (AFP Promoter) the whole adenovirus carrier of control.The afp promoter downstream is a reporter gene alkaline phosphatase gene (AP).With inserting separaant HS4 before the afp promoter sequence in the M001 recombinant adenovirus genome, form recombinant adenovirus M002, in order to the liver cancer-specific of research afp promoter and separaant.For carrying out actual pharmacodynamic study and clinical application, with the alkaline phosphatase gene place to go in above two recombinant adenoviral vectors, replace adenovirus E 1 a gene, form two tumour-specific virus vector A001 and A002, purpose provides a kind of adenovirus carrier and can specificly duplicate in liver cancer cell, express the E1a gene, thus differential high efficient kill liver cancer cell.
The afp promoter complex structure, sequence reaches 8kb.Use different piece, its liver cancer-specific has very big difference.This project adopts gene engineering method that the human a-fetoprotein promoter structure is optimized, specifically, adopt twice multiple enhanser (Enhancer), six multiple (Silencer) of mourning in silence, and afp promoter core area, common form one brand-new, compact, afp promoter efficiently, 5 type adenoviral gene groups are placed under this promotor control, and, form one and can specificity in liver cancer cell, duplicate the recombinant adenovirus of expression in conjunction with regulation and control assemblies such as separaants (Isolator).Advantage of the present invention:
The invention solves two problems in the gene therapy of liver cancer field:
(1) how at the expressing gene of liver cancer cell internal specific, by using the recombinant adenoviral vector of afp promoter control, can be at the specifically inside tumor cell table
Reach foreign gene, if specifically expressing be some cytotoxicity foreign genes or with apoptosis-related foreign gene, a kind of effective means will be provided the treatment of liver cancer.Adopt the tumor-specific promoters of different targets, just can carry out specific treatment at different tumours.
(2) how to improve the tumour-specific of gene therapy of liver cancer carrier.The common problem that has poor specificity of present therapy of tumor carrier.Employed recombinant adenoviral vector among the present invention utilizes the design of inserting separaant, improves the specificity of duplicating and expressing of virus vector in tumour cell.
Definition
Unless different definition is arranged in addition, as used herein common understand the same of those skilled in the art in the field under the implication of all technology and scientific terminology and the present invention.Although similar or identical any method any and described here and material all can be used for enforcement of the present invention or test.Only preferable methods and material are described at this.For the present invention is now defined with regard to following term:
" foreign gene " this term refers to insert the dna sequence dna of any protein of interest of coding in the used adenovirus carrier among the present invention as used herein.The upper limit of inserting foreign gene length depends on the packing limit of adenovirus carrier.The albumen that any institute of the foreign gene codified that inserts needs can have medicinal or further feature.Foreign gene can get with the ordinary method preparation, as synthetic, and is got by natural origin extraction, clone etc.
These two terms of " liver cancer-specific genetic expression " and " liver cancer-specific " are meant the expression of adenovirus carrier in liver cancer cell as used herein.Though this carrier also has expression in normal cell, expression level is very low, makes carrier duplicate and packs and can't effectively carry out, to such an extent as to low like this copy package level can be ignored.
" first-generation adenovirus carrier " or " first-generation recombinant adenoviral vector " this term is meant any adenovirus carrier as used herein, has deleted E1 and/or E3 district gene, causes not reproducible of adenovirus carrier.
The structure of the structure 1.M001 virus of example I recombinant adenovirus M001 and M002
The structure of M001, M002 two recombinant adenovirus has below been described.They all are the 5 type adenovirus carriers that have afp promoter, and wherein the M002 recombinant adenovirus also contains separaant HS4 gene, and M001 does not contain the HS4 gene.
Unless otherwise indicated, the technology used in the present invention all is this area routine techniquess, and as molecule clone technology, microbiological technique, cytobiology technology, these technology all are fully explained in the literature.As " molecular cloning laboratory manual " second edition (1989) of Sambrook etc. etc.
The structure of plasmid vector:
With EcoRI and NsiI restriction endonuclease cutting plasmid pLAPSN, reclaim the dna fragmentation that contains the AP gene.With SalI and AflII restriction endonuclease cutting plasmid pXZAFP, reclaim big fragment.
With AvrII and BlpI cutting plasmid pAd.BG, reclaim big fragment.Respectively the AP gene is connected with this fragment with the AFP promoter gene, constitutes plasmid pM001.Adopt the calcium phosphate precipitation method with plasmid pM001 and plasmid pBHG10 cotransfection 293 cells, cell surface is spread 0.5% agar, include 1XMEM, 7% foetal calf serum places 37 ℃, 5%CO
2Incubator is cultivated, and after about 9 days, plaque appears in cell under the culture dish agar layer, and the picking plaque increases, and extracts recombinant dna, carries out the DNA restriction analysis, determines correct recombinant adenovirus poison strain.2.M002 the structure of virus
The construction process of M002 recombinant adenovirus is that the HS4 gene is inserted AFP promoter sequence 5 ' end in the pM001 plasmid, forms plasmid pM002, then with plasmid pBHG10 cotransfection 293 cells, cell surface is spread 0.5% agar, include 1XMEM, 7% foetal calf serum, place 37 ℃, 5%CO
2Incubator is cultivated, and after about 9 days, plaque appears in cell under the culture dish agar layer, and the picking plaque increases, and extracts recombinant dna, carries out the DNA restriction analysis, determines correct recombinant adenovirus poison strain.
Embodiment 2
The structure of A001 recombinant virus and A002 recombinant virus
Method with point mutation constructs an AgeI restriction enzyme site before pXC1 plasmid E1a gene, with AgeI and HpaI restriction enzyme the E1a gene is cut down, and reclaims gene fragment.
With the excision of the alkaline phosphatase gene in pM001 and the pM002 plasmid, replace the E1a gene.Constitute plasmid pA001 and pA002 respectively, with plasmid pA001 and pA002 respectively with plasmid pBHG10 cotransfection 293 cells, cell surface is spread 0.5% agar, include 1XMEM, 7% foetal calf serum places 37 ℃, 5%CO
2Incubator is cultivated, and after about 9 days, plaque appears in cell under the culture dish agar layer, and the picking plaque increases, and extracts recombinant dna, carries out the DNA restriction analysis, determines correct recombinant adenovirus poison strain A001 and A002.
M001 and the specificity of M002 recombinant virus in liver cancer cell are duplicated and are expressed
M001 and M002 recombinant adenovirus are incubated in 293 cells, and culture condition is the DMEM substratum, 10% foetal calf serum, 37 ℃, 5%CO
2Use the cesium chloride density gradient centrifugation purified virus, 35000rpm two times centrifugal purified virus contains 1mM MgCl with rare being assigned in of virus at last
2, 10mM Tris, pH7.5 is in the solution of 10% glycerine.
With M001 virus, M002 virus vector and wild-type adenovirus infect HepG2 cell (human liver cancer cell) with multiplicity of infection (MOI=100), Hep3B cell (human liver cancer cell), LOVO cell (human large intestine cancer cell strain), HeLa cell (human cervical carcinoma cell strain), 293 cells (the human embryonic kidney cell that 5 type adenovirus transform, support the non-replicating adenovirus carrier to duplicate), BT549 (human breast cancer cell), the human fibroblasts, people's normal liver cell is HumHep, MCF-7 (human breast cancer cell) and LS174T (human colon cancer cell).Above cell is incubated at respectively in 96 orifice plates, and culture condition is the DMEM substratum, 10% foetal calf serum, 37 ℃, 5%CO
2After 48 hours,, carry out alkaline phosphatase activities and detect, the results are shown in Figure 3 lysis.As can be seen from Fig. 3, for the HepG2 cell of expressing alpha-fetoprotein, Hep3B cell HuH7 cell, M001 virus and M002 virus have shown high specificity, wherein the specificity of M002 virus is higher.In other tumour cells of not expressing alpha-fetoprotein and normal cell, two viruses are not expressed reporter gene substantially.
Although the present invention for the ease of clearly understanding by way of example mode describe in detail in some aspects, it is feasible obviously carrying out certain variation and modification within the scope of the claims.
Claims (23)
1. recombinant adenoviral vector, it has deleted E1 and/or E3 district gene, and E1 district promotor, and has and can specificity duplicate the external source insertion gene of expression in tumour cell.
2. one kind by the virus vector in the claim 1, and it is virus genomic to duplicate and be expressed under the exogenous promoter control.
3. adenovirus carrier described in the claim 2 has separaant (isolator) sequence, to strengthen the specificity of exogenous promoter on the left of the exogenous promoter sequence in its viral genome.
4. adenovirus carrier described in the claim 2, form by following several assemblies:
A. terminal repeat is inverted in one section adenovirus left side.
B. one section adenovirus packaging sequence is positioned at the 3 ' end that terminal repeat is inverted in the left side.
C. one section separaant sequence is positioned at 3 ' of left side adenovirus packaging sequence and holds.
C. one section exogenous promoter sequence is positioned at 3 ' of left side separaant sequence and holds.
D. a fragment gene sequence, it duplicates with expression and places under the exogenous promoter control, is positioned at 3 ends of exogenous promoter '.
E. one or more adenoviral genes are positioned at 3 ' end of the gene that exogenous promoter and control thereof expresses.
F. tumor-necrosis factor glycoproteins is inverted on the adenovirus right side, is positioned at 3 ' end of adenoviral gene.
5. an adenovirus carrier has one section bidirectional transcription termination site sequence behind 3 ' end of the insertion gene order that the exogenous promoter control table reaches, and can block to transcribe and carry out.
6. adenovirus carrier described in the claim 2, its promotor that has is a tumor-specific promoters.
7. adenovirus carrier described in the claim 2, its promoter sequence that has is alpha-fetoprotein (AFP) promoter sequence.
8. adenovirus carrier described in the claim 2, the afp promoter sequence that it has are by enhanser (Enhancer), and son of mourning in silence (Silencer) and promotor core area (core promoter) constitute.
9. adenovirus carrier described in the claim 2, the enhancer sequence of the afp promoter sequence that it has has twice repetition, and the subsequence of mourning in silence has 6 to 8 repetitions.
10. adenovirus carrier described in the claim 3, separaant sequence wherein be one section by the sequence that gets in the chicken gene, i.e. separaant HS4, or other has the exogenous DNA array of said function.
11. adenovirus carrier described in the claim 4, external source is wherein inserted dna sequence dna and is expressed one or more gene products.
12. adenovirus carrier described in the claim 4, its termination site are two-way SV40 poly adenosine sequences.
13. adenovirus carrier described in the claim 4, its termination site are two-way poly adenosine sequences.
14. adenovirus carrier described in the claim 4, the insertion gene product of tumor-specific promoters control wherein is apoptosis gene or lysis gene product.
15. adenovirus carrier described in the claim 3, the insertion gene product of tumor-specific promoters control wherein is the alkaline phosphatase gene product.
16. adenovirus carrier described in the claim 3, it is adenovirus E 1 a gene that external source is wherein inserted gene.
17. adenovirus carrier described in the claim 4, the insertion gene of tumor-specific promoters control wherein is a suicide gene.
18. the method for a selectivity kill tumor cell, this method is included under the infectious condition, but any one adenovirus carrier among the claim 2-17 of kill tumor cell is contacted with the cell colony that contains tumour cell, therefore produce a kind of cell colony of infection.
19. a pharmaceutical composition, but contain recombinant adenoviral vector any among the claim 4-19 of kill tumor cell and available pharmaceutical carrier.
20. according to the method for claim 19, it also comprises this tumour cell is contacted a kind of immunosuppression or chemotherapy compound.
21. a composition, it comprises a kind ofly having the recombinant adenovirus that is selected from any one adenovirus characteristic among the claim 2-17, and a kind of chemotherapy compound.
22. a composition, it comprises a kind ofly having the recombinant adenovirus that is selected from any one adenovirus characteristic among the claim 2-17, and a kind of immunosuppressive compounds.
23. any described virus is used for the treatment of purposes in the pharmaceutical composition of tumour in preparation among the claim 2-17.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011343141A CN1294269C (en) | 2001-10-29 | 2001-10-29 | Adenovirus carrier for specifically killing primary liver cancer cells and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011343141A CN1294269C (en) | 2001-10-29 | 2001-10-29 | Adenovirus carrier for specifically killing primary liver cancer cells and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1379109A true CN1379109A (en) | 2002-11-13 |
| CN1294269C CN1294269C (en) | 2007-01-10 |
Family
ID=4672408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011343141A Expired - Fee Related CN1294269C (en) | 2001-10-29 | 2001-10-29 | Adenovirus carrier for specifically killing primary liver cancer cells and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1294269C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387710C (en) * | 2003-01-28 | 2008-05-14 | 上海三维生物技术有限公司 | Therapy for primary and metastatic cancers |
| CN100415298C (en) * | 2003-09-10 | 2008-09-03 | 上海三维生物技术有限公司 | Adenovirus vector for idiopathy liver genetherapy and using method |
| CN100420742C (en) * | 2003-09-29 | 2008-09-24 | 中国人民解放军军事医学科学院基础医学研究所 | Oncolytic adenovirus with target for liver cancer and its preparation method and use |
| CN1871034B (en) * | 2003-07-09 | 2011-07-06 | 亨利福特保健系统公司 | Methods and compositions for cancer therapy using a novel adenovirus |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US629220A (en) * | 1897-05-04 | 1899-07-18 | William W Uhlinger | Harness-evening mechanism for looms. |
| US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US6096718A (en) * | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| CN1258738A (en) * | 1998-12-31 | 2000-07-05 | 上海华晨生物技术研究所 | Recombined adenovirus expressing the stimulating factor of human granulocyte-macrophage colony and its preparation and use |
| CN100415298C (en) * | 2003-09-10 | 2008-09-03 | 上海三维生物技术有限公司 | Adenovirus vector for idiopathy liver genetherapy and using method |
-
2001
- 2001-10-29 CN CNB011343141A patent/CN1294269C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387710C (en) * | 2003-01-28 | 2008-05-14 | 上海三维生物技术有限公司 | Therapy for primary and metastatic cancers |
| CN1871034B (en) * | 2003-07-09 | 2011-07-06 | 亨利福特保健系统公司 | Methods and compositions for cancer therapy using a novel adenovirus |
| CN100415298C (en) * | 2003-09-10 | 2008-09-03 | 上海三维生物技术有限公司 | Adenovirus vector for idiopathy liver genetherapy and using method |
| CN100420742C (en) * | 2003-09-29 | 2008-09-24 | 中国人民解放军军事医学科学院基础医学研究所 | Oncolytic adenovirus with target for liver cancer and its preparation method and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1294269C (en) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gluzman | SV40-transformed simian cells support the replication of early SV40 mutants | |
| Kim et al. | Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy | |
| EP0689447B1 (en) | Cytopathic viruses for therapy and prophylaxis of neoplasia | |
| US5677178A (en) | Cytopathic viruses for therapy and prophylaxis of neoplasia | |
| JP5746823B2 (en) | Adenovirus having a mutation in the endoplasmic reticulum retention domain of E3-19K protein and its use in cancer therapy | |
| Ross et al. | Identification of the adenovirus early proteins and their genomic map positions | |
| US6080578A (en) | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia | |
| US6296845B1 (en) | Selective killing and diagnosis of p53+ neoplastic cells | |
| Hamada et al. | Growth Inhibition of Human Cervical Cancer Cells with the Recombinant Adenovirusp53 in Vitro | |
| CN102260712B (en) | Construction and application of type B adenovirus hominis Ad11 mutant with enhanced tumor dissolving ability | |
| Chang et al. | Transformation of human cultured fibroblasts with plasmids carrying dominant selection markers and immortalizing potential | |
| CN101092636B (en) | Selectively replicating viral vectors, preparation method and application | |
| CN1294269C (en) | Adenovirus carrier for specifically killing primary liver cancer cells and its application | |
| CN1328372C (en) | Tumor target gene-virus ZD55-IL-24, construction method and application thereof | |
| CN1294268C (en) | Recombinant adenovirus vector capable of being duplicated and spread specifcally inside tumor cell | |
| Ma et al. | E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer | |
| McDougall et al. | Recent studies on the characteristics of adenovirus-infected and-transformed cells | |
| CN1793343A (en) | Tumourolytic anticancer recombined adenovirus with tumour target direction and idioctonia | |
| Doerfler | Adenoviruses | |
| CN1509764A (en) | Preparation of target gene virus medicine against cancers | |
| Moreno-Lopez et al. | Papillomavirus DNA associated with pulmonary fibromatosis in European elks | |
| Su et al. | Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma | |
| WO2021249035A1 (en) | Replication-type human adenovirus and application thereof | |
| KR100357054B1 (en) | Tumor-Specific Recombinant Adenovirus and Method for Tumor-Specific Transformation by The Same | |
| Ganly | E1B attenuated adenoviral therapy for recurrent squamous cell cancer of the head and neck |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070110 Termination date: 20131029 |